Halozyme Therapeutic (HALO)

$70.93 +4.52 (6.81%)
Market Cap 7.87B
Revenue (ttm) 1.40B
Net Income (ttm) 316.89M
EPS (ttm) N/A
PE Ratio 16.96
Forward PE 8.35
Profit Margin 22.69%
Debt to Equity Ratio 43.90
Volume 4,855,900
Avg Vol 1,542,794
Day's Range N/A - N/A
Shares Out 118.47M
Stochastic %K 74%
Beta 0.89
Analysts Sell
Price Target $85.78

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md May. 13 at 4:55 AM
$HALO $HALO $HALO Halozyme has 3 MDASE patents that are ineligible for PGR’s by Merck. This means that Halozyme still has a strong chance to win the trial in the NJ District court just like it did in the German court. Merck won this PTAB battle but the war is far from over! You don’t have to take my word for it, look at the price action for Alteogen since the PTAB decison was announced. After a short lived spike, it’s only up 3%. Even Alteogen’s own investors know that this is far from over. Merck and Alteogen stole halozyme’s technology and one way or another they will pay for it!
0 · Reply
Sean29md
Sean29md May. 13 at 4:01 AM
$HALO $HALO Halozyme has 3 Enhanze patents that are ineligible for PGR’s by Merck. This means that Halozyme still has a strong chance to win the trial in the NJ District court just like it did in the German court. Merck won this PTAB battle but the war is far from over! You don’t have to take my word for it, look at the price action for Alteogen since the PTAB decison was announced. After a short lived spike, it’s only up 3%. Even Alteogen’s own investors know that this is far from over. Merck and Alteogen stole halozyme’s technology and one way or another they will pay for it!
0 · Reply
Optionshmoptions
Optionshmoptions May. 12 at 6:05 PM
$HALO appears to be it
0 · Reply
Optionshmoptions
Optionshmoptions May. 12 at 5:53 PM
$HALO that it for today?
0 · Reply
Blockwave1
Blockwave1 May. 12 at 5:32 PM
$HALO 75 Call 5/15 @ 0.35 Now .85 for 200% Sold these this AM for 100% rather than 200% 🙂‍↕️
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial May. 12 at 5:22 PM
Gamma Squeeze idea 💡 $HALO 80 Call 6/18 at 1.20
0 · Reply
Doozio
Doozio May. 12 at 3:38 PM
Have no fear da $HALO is here to protect YO 🐑 as da 🧠 rotation is on the DLO n shud begin to make $XBI STOKs $EXEL ONTO 🐒🍌🧠⏰♾️
0 · Reply
French_Vibe
French_Vibe May. 12 at 12:13 PM
$HALO I'm wondering about the risk of delta hedging with this stock. It could cap the price at $75-80. Any thoughts?
1 · Reply
MarketBeat
MarketBeat May. 12 at 12:10 AM
https://marketbeat.com/a/8649051/ $HALO Halozyme Therapeutics Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 11 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-5-11-halozyme-therapeutics-inc-stock/ $HALO Halozyme Therapeutics Earnings Transcript
0 · Reply
Latest News on HALO
Halozyme price target lowered to $93 from $96 at Morgan Stanley

2026-05-12T16:13:22.000Z - 19 hours ago

Halozyme price target lowered to $93 from $96 at Morgan Stanley

Halozyme Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 1 day ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2026

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

May 11, 2026, 4:01 PM EDT - 1 day ago

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme announces global collaboration and license agreement with GSK

2026-05-07T19:48:39.000Z - 5 days ago

Halozyme announces global collaboration and license agreement with GSK

GSK

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

May 7, 2026, 9:00 AM EDT - 5 days ago

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

2026-05-07T06:12:19.000Z - 6 days ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

ORKA

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

May 6, 2026, 8:00 AM EDT - 7 days ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

ORKA

Halozyme Therapeutics Transcript: AGM 2026

May 5, 2026, 12:00 PM EDT - 7 days ago

Halozyme Therapeutics Transcript: AGM 2026

Halozyme to Report First Quarter 2026 Financial and Operating Results

Apr 30, 2026, 4:30 PM EDT - 12 days ago

Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme names Darren Snellgrove as CFO

2026-04-30T17:01:40.000Z - 12 days ago

Halozyme names Darren Snellgrove as CFO

JNJ

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Halozyme price target raised to $95 from $90 at H.C. Wainwright

2026-04-29T10:25:50.000Z - 14 days ago

Halozyme price target raised to $95 from $90 at H.C. Wainwright

Halozyme price target raised to $96 from $94 at Morgan Stanley

2026-04-21T12:51:13.000Z - 21 days ago

Halozyme price target raised to $96 from $94 at Morgan Stanley

Halozyme enters global global collaboration and license agreement with Vertex

2026-04-07T12:23:24.000Z - 5 weeks ago

Halozyme enters global global collaboration and license agreement with Vertex

VRTX

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme names David Ramsay as Interim CFO

2026-03-12T12:38:03.000Z - 2 months ago

Halozyme names David Ramsay as Interim CFO

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Mar 12, 2026, 8:30 AM EDT - 2 months ago

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:45 AM EDT - 2 months ago

Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Mar 6, 2026, 8:00 AM EST - 2 months ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Halozyme to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 2 months ago

Halozyme to Participate in Upcoming Investor Conferences

Halozyme price target raised to $94 from $78 at Morgan Stanley

2026-02-19T13:43:22.000Z - 2 months ago

Halozyme price target raised to $94 from $78 at Morgan Stanley

Halozyme price target raised to $90 from $75 at Benchmark

2026-02-19T13:36:39.000Z - 2 months ago

Halozyme price target raised to $90 from $75 at Benchmark

Halozyme price target raised to $75 from $65 at Wells Fargo

2026-02-19T11:32:57.000Z - 2 months ago

Halozyme price target raised to $75 from $65 at Wells Fargo

Halozyme Therapeutics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 3 months ago

Halozyme Therapeutics Earnings Call Transcript: Q4 2025

Halozyme reports Q4 EPS 24c vs. $1.26 last year

2026-02-17T21:05:28.000Z - 3 months ago

Halozyme reports Q4 EPS 24c vs. $1.26 last year

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 17, 2026, 4:01 PM EST - 3 months ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 4:05 PM EST - 3 months ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Therapeutics Transcript: Investor update

Jan 28, 2026, 8:30 AM EST - 3 months ago

Halozyme Therapeutics Transcript: Investor update

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 3 months ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 4 months ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Leerink views ‘major deal’ on Entyvio as positive for Halozyme

2026-01-08T18:40:15.000Z - 4 months ago

Leerink views ‘major deal’ on Entyvio as positive for Halozyme

TAK

Halozyme price target raised to $90 from $79 at TD Cowen

2026-01-08T14:43:27.000Z - 4 months ago

Halozyme price target raised to $90 from $79 at TD Cowen

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 4 months ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 4 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 5 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 5 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 5 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 5 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 1:20 PM EST - 5 months ago

Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 6 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 6 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 6 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 6 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 6 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 6 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 6 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 6 months ago

Halozyme Therapeutics Earnings Call Transcript: Q3 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 6 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 7 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 7 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme Therapeutics Transcript: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 7 months ago

Halozyme Therapeutics Transcript: M&A Announcement

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 8 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:45 AM EDT - 8 months ago

Halozyme Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Halozyme Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 1:30 PM EDT - 8 months ago

Halozyme Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 9 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Halozyme Therapeutics Earnings Call Transcript: Q2 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 10 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 10 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 10 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 11 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 11 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:00 AM EDT - 1 year ago

Halozyme Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:20 PM EDT - 1 year ago

Halozyme Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Halozyme Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 1 year ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 1 year ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 6:15 PM EDT - 1 year ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 9, 2025, 8:45 AM EDT - 1 year ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Apr 7, 2025, 9:29 AM EDT - 1 year ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 1 year ago

Halozyme Joins the $1 Billion Club

Halozyme Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Halozyme Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Sean29md
Sean29md May. 13 at 4:55 AM
$HALO $HALO $HALO Halozyme has 3 MDASE patents that are ineligible for PGR’s by Merck. This means that Halozyme still has a strong chance to win the trial in the NJ District court just like it did in the German court. Merck won this PTAB battle but the war is far from over! You don’t have to take my word for it, look at the price action for Alteogen since the PTAB decison was announced. After a short lived spike, it’s only up 3%. Even Alteogen’s own investors know that this is far from over. Merck and Alteogen stole halozyme’s technology and one way or another they will pay for it!
0 · Reply
Sean29md
Sean29md May. 13 at 4:01 AM
$HALO $HALO Halozyme has 3 Enhanze patents that are ineligible for PGR’s by Merck. This means that Halozyme still has a strong chance to win the trial in the NJ District court just like it did in the German court. Merck won this PTAB battle but the war is far from over! You don’t have to take my word for it, look at the price action for Alteogen since the PTAB decison was announced. After a short lived spike, it’s only up 3%. Even Alteogen’s own investors know that this is far from over. Merck and Alteogen stole halozyme’s technology and one way or another they will pay for it!
0 · Reply
Optionshmoptions
Optionshmoptions May. 12 at 6:05 PM
$HALO appears to be it
0 · Reply
Optionshmoptions
Optionshmoptions May. 12 at 5:53 PM
$HALO that it for today?
0 · Reply
Blockwave1
Blockwave1 May. 12 at 5:32 PM
$HALO 75 Call 5/15 @ 0.35 Now .85 for 200% Sold these this AM for 100% rather than 200% 🙂‍↕️
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial May. 12 at 5:22 PM
Gamma Squeeze idea 💡 $HALO 80 Call 6/18 at 1.20
0 · Reply
Doozio
Doozio May. 12 at 3:38 PM
Have no fear da $HALO is here to protect YO 🐑 as da 🧠 rotation is on the DLO n shud begin to make $XBI STOKs $EXEL ONTO 🐒🍌🧠⏰♾️
0 · Reply
French_Vibe
French_Vibe May. 12 at 12:13 PM
$HALO I'm wondering about the risk of delta hedging with this stock. It could cap the price at $75-80. Any thoughts?
1 · Reply
MarketBeat
MarketBeat May. 12 at 12:10 AM
https://marketbeat.com/a/8649051/ $HALO Halozyme Therapeutics Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 11 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-5-11-halozyme-therapeutics-inc-stock/ $HALO Halozyme Therapeutics Earnings Transcript
0 · Reply
Sean29md
Sean29md May. 11 at 9:33 PM
$HALO Tour de force earnings call! Enjoy a sustained run up in share price.
0 · Reply
Doozio
Doozio May. 11 at 9:24 PM
On an eps gap above the 200d as da FATE of da YO slaps a $HALO ONTO 🐒🍌🧠⏰♾️
0 · Reply
Jblack500
Jblack500 May. 11 at 8:43 PM
$HALO biotechs haven't been acting great. Double beat and buyback would like to see channel top break tomorrow
0 · Reply
jw56502
jw56502 May. 11 at 8:43 PM
$HALO This is a 10b MV company. High cash flow, pipeline/sales only growing at an already high activity rate, financial clean up and clarity on replacing their main product revenue engine in 2029+.....oh and the perpetual minimum 3% shareholder return every year (not to mention AT LEAST a 400m buy back in FY26 for a total of a 1b program).
0 · Reply
Jblack500
Jblack500 May. 11 at 8:40 PM
$HALO huge buyback. Potential to reduce the float by over 10%
1 · Reply
Junkway2000
Junkway2000 May. 11 at 8:32 PM
$HALO
0 · Reply
Sean29md
Sean29md May. 11 at 8:27 PM
$HALO Does anyone have a link to the live CC? Halo website is not showing it.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 11 at 8:13 PM
$HALO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.27 up 32.29% YoY • Reported revenue of $376.71M up 42.23% YoY • Halozyme's Board of Directors authorized a new capital return program to repurchase up to $1B of outstanding common stock by December 31, 2028, with at least $400M expected in 2026.
1 · Reply
oside2006
oside2006 May. 11 at 8:06 PM
$HALO $1.X billion new share repurchasing
0 · Reply
Cutlass
Cutlass May. 11 at 8:03 PM
$HALO Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate BENZINGA 3:03 PM ET 5/11/2026
0 · Reply
chestergiordano
chestergiordano May. 11 at 8:01 PM
$HALO huge beat!!! It’s at $76!!
0 · Reply
chestergiordano
chestergiordano May. 11 at 3:36 PM
$HALO $55 by tomorrow
3 · Reply